Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–66 of 66 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Dysfunction-Associated Steatohepatitis Clear all

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control); Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Low-oxalate fixed diet; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Interventions: Efinopegdutide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 36
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions: Metabolic surgery, Incretin-Based Therapy; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions: BI 770371, Placebo for BI 770371; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Coronado, California • Montclair, California + 8 more

Conditions: Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions: Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications; Behavioral
Lead sponsor: Grand Valley State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wyoming, Michigan

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions: Pegozafermin, Placebo; Biological · Drug
Lead sponsor: 89bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 762 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 149
States / cities: Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 122 more

Conditions: Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: STIRRED; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 4,704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Food Insecurity
Interventions: Food Security Screening & Referral Program; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 5 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 57
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 44 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis
Interventions: Survodutide, Placebo matching survodutide; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 126
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more

Conditions: Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions: BMN 255, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more

Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 165
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more

Conditions: Liver Cirrhosis
Interventions: BI 3802876, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Chandler, Arizona • Coronado, California • La Mesa, California + 21 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: North Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 6 more

Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Interventions: Efinopegdutide, Placebo; Combination Product
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more

Search by objective public record fields.

Isocaloric Navy-Bean Substitution in Adults With MASLD

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

Fibrosis Lessens After Metabolic Surgery

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

Implementing Food Referrals for Equity and Sustained Health

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)